Title : HIV-1 Vpr Abrogates the Effect of TSG101 Overexpression to Support Virus Release.

Pub. Date : 2016

PMID : 27648839






8 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 However, some reports show that overexpression of TSG101 inhibits virus release by disruption of Gag targeting process. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
2 Co-transfection of TSG101 and Gag with Vpr prevented TSG101-induced Gag accumulation in endosomes and lysosomes. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
3 Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
4 Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
5 Vpr and Gag interaction is required to counteract TSG101 overexpression effect since Vpr A30F mutant which is unable to interact with Gag and incorporate into virions, reduced ability to prevent Gag accumulation and to rescue VLP production. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
6 In addition, GST pull-down assays and Biacore analysis revealed that Vpr competed with TSG101 for Gag binding. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
7 These results indicate that Vpr overcomes the effects of TSG101 overexpression to support viral production by competing with TSG101 to bind Gag. Glycosaminoglycans tumor susceptibility 101 Homo sapiens
8 These results indicate that Vpr overcomes the effects of TSG101 overexpression to support viral production by competing with TSG101 to bind Gag. Glycosaminoglycans tumor susceptibility 101 Homo sapiens